Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at help@authorea.com in case you face any issues.

Havva İpek Demir

and 53 more

not-yet-known not-yet-known not-yet-known unknown Background: Allergic bronchopulmonary aspergillosis (ABPA), which is one of the respiratory complications of cystic fibrosis, is a hypersensitivity reaction in the lung against the antigens of the fungus Aspergillus fumigatus ( A.fumigatus). If left untreated, it may cause irreversible deteriorations in lung functions. The aim of this study is to determine the incidence of ABPA, according to years and to determine the risk factors leading to the development of ABPA by using the CF Registry System of Turkey data. Methods: The study was designed as a retrospective cohort study. Using the CF Registry System of Turkey data, the incidence of ABPA was determined and the data of 44 patients newly diagnosed with ABPA in 2022 and 132 patients with similar mutation weight and age range without ABPA diagnosis in that year were compared, and the risk factors affecting the development of ABPA were determined. Results: Low pulmonary function test values, having had at least one pulmonary exacerbation in that year and receiving intravenous antibiotic treatment, using inhaled antibiotics, having a high number of pulmonary exacerbations, having Pseudomonas aeroginosa (P.aeroginosa) colonization, having a low body mass index (BMI) and having cystic fibrosis related diabetes mellitus (CFRD) were found to be among the risk factors for the development of ABPA. Conclusions: Early recognition and treatment of ABPA is essential to prevent further damage to the lungs. Patients with frequent pulmonary exacerbations, low BMI and low pulmonary function test values, chronic colonization should definitely be considered for ABPA.

kamil YILMAZ

and 1 more

Objective: In this study, we aimed to determine the prevalence and clinical importance of vitamin D deficiency in children and adolescent patients who were hospitalized with the diagnosis of COVID-19. Material and Methods: 40 patients who were diagnosed to have COVID-19 and hospitalized with the real-time reverse transcription polymerase chain reaction (RT-PCR) method were included. The control group consisted of 45 healthy patients with normal vitamin D levels. The age of admission, clinical and laboratory data, and 25-hydroxycholecalciferol (25-OHD) and parathormone (PTH) levels were recorded. Those with vitamin D levels which are below 20 ng/ml were determined as Group 1 and those with ≥20 ng/ml as Group 2. Results: The median levels of vitamin D level were 13.14 (4.19-69.28) in the group of patients with COVID-19 and 34.81(3.8-77.42) in the control group. Compared to the control group, there was a statistically significantly lower vitamin D level (p <0.001) in the COVID-19 patient group. At admission, the symptom of fever was significantly higher in Group 1 than in Group 2 (p =0.038). The distribution of disease severity according to vitamin D levels was not found significantly different. In conclusion; our study is the first to evaluate vitamin D levels and its relationship with clinical findings in pediatric patients diagnosed with COVID-19. There are significantly lower levels of vitamin D in children with COVID-19 than those in the control group. This shows that vitamin D, which is effective in the immunological mechanism, also has an effect in the physiopathology of the disease.